TY - JOUR
T1 - Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias
AU - Dokholyan, Nikolay V.
AU - Mohs, Richard C.
AU - Bateman, Randall J.
N1 - Funding Information:
N.V.D. is the President of the Molecules in Action LLC. He also serves on the advisory board at Atom Bioworks. He also serves as the Editor‐in‐Chief of . R.C.M. is the Chief Science Officer for the Global Alzheimer's Platform (GAP) Foundation and Vice President for Clinical Development at Agenebio, Inc. a Baltimore‐based biotechnology company; he is PI for NIA Grant R01AG061091 “A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease” awarded to AgeneBio. He is member of the Board of Governors for the Alzheimer's Drug Discovery Foundation (ADDF), and a member of the Board of Directors for CogState, Ltd. He has received consulting fees from Vaxxinity, Inc., Amyriad Therapeutics, and the MD Anderson Cancer Center, Center for Neurodegeneration. R.J.B. has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B. has received honoraria as a speaker, consultant, or advisory board member from Amgen and Roche. Proteins
Funding Information:
Federal grant programs, specifically those sponsored by the NIH, offer support for both fundamental and translational biomedical research. At the NIH, scientific merit reviews are performed by scientists, and, therefore, offer a broad and fair coverage of research directions. These grant programs are highly competitive, and thus proposals that offer something radically different and risky (“high risk, high reward”) tend to fare worse than risk‐averse proposals that continue established lines of research. While the NIH has provided venues for high‐risk high‐return projects, they remain extremely competitive, especially for younger scientists and those with new ideas who come from outside of a traditional neuroscience background.
Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - The health, well-being, and financial security of Americans are greatly impacted by Alzheimer's disease. The forecast paints an upward trajectory with the number of Americans suffering from Alzheimer's disease and related dementia. To discuss the Alzheimer's crisis, The Senate Committee on Finance, Subcommittee on Health Care, held a hearing titled, “The Alzheimer's Crisis: Examining, Testing, and Treatment Pipelines and Fiscal Implications,” on December 16, 2020. Here, we summarize and expand on the discussion of the panel and its review of recent progress, ongoing challenges associated with Alzheimer's disease, and potential initiatives that promise to speed progress in developing treatments and improving care.
AB - The health, well-being, and financial security of Americans are greatly impacted by Alzheimer's disease. The forecast paints an upward trajectory with the number of Americans suffering from Alzheimer's disease and related dementia. To discuss the Alzheimer's crisis, The Senate Committee on Finance, Subcommittee on Health Care, held a hearing titled, “The Alzheimer's Crisis: Examining, Testing, and Treatment Pipelines and Fiscal Implications,” on December 16, 2020. Here, we summarize and expand on the discussion of the panel and its review of recent progress, ongoing challenges associated with Alzheimer's disease, and potential initiatives that promise to speed progress in developing treatments and improving care.
KW - ADRD
KW - Alzheimer's disease
KW - dementia
KW - healthcare policy
UR - http://www.scopus.com/inward/record.url?scp=85145084148&partnerID=8YFLogxK
U2 - 10.1002/trc2.12330
DO - 10.1002/trc2.12330
M3 - Article
C2 - 35910674
AN - SCOPUS:85145084148
SN - 2352-8737
VL - 8
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
IS - 1
M1 - e12330
ER -